Neuralink is planning trials to determine if its brain chip implant can control an “investigational assistive robotic arm.” ...

US-based Neuralink has received approval to launch a new feasibility trial studying its brain implant linked with an ...

Trump’s FDA pick, Marty Makary, appears to be quelling fears about a major disruption to biotech and pharma. Neuralink ...

Neuralink says that the study's launch is an important step towards restoring not just digital but also physical freedom.

PTC Therapeutics will scrap development of its treatment for amyotrophic lateral sclerosis after it failed to meet a primary endpoint in a Phase 2 trial.

LOS ANGELES and SAN FRANCISCO and HONOLULU, Nov. 26, 2024 /PRNewswire/ -- Each November, the ALS <a target=_blank href=https: ...

Why are high heels bad for your health? From posture issues to foot deformities, here's how heels impact your body and how to ...

PTC Therapeutics said on Tuesday it is discontinuing the development of its drug for a type of fatal neurodegenerative disease, as it failed to slow disease progression in a mid-stage trial. This ...

The upcoming Burj Azizi on Sheikh Zayed Road aims to push the boundaries of Dubai’s architectural innovation—figuratively and ...

England have been preparing for this series years in advance, looking to win Down Under for the first time in 15 years, while ...

Scherzinger recently took to Instagram to share her workout routine, showcasing strength training, squats, lunges, pulldowns, ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the global Phase 2 placebo-controlled CardinALS study did not meet its primary endpoint of slowing disease progression on the composite ...